More recently, a study evaluating 50 primary SCCHN tumors for activated phospho-Src (P-Src), E-cadherin, and vimentin expression by immunohistochemical staining found increased P-Src, decreased E-cadherin, and presence of vimentin expression in SCCHN tumors to be significantly associated (P < .05) with morphologies associated with aggressive cancers including penetrating invasive fronts, poor or sarcomatoid differentiation, and lymph node metastases [79]. This evidence concerns the gene SRC and cancer.